Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
INSERM maintains 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct art units, showing a diverse technical footprint even within a single broad category. The prosecution involves distinct examiners, ensuring that each pending matter is being reviewed by a different individual at the patent office. This structure requires the applicant to tailor their responses to the specific scientific expertise of each examiner involved.
VYAS, KEYUR ANILKUMAR is the busiest examiner for the portfolio, currently managing 1 pending office action. With the active matters spread across 2 distinct art units, the portfolio requires a strategy that addresses the specific standards of different administrative divisions. This distribution suggests that INSERM is navigating multiple specialized tracks within the Biotechnology & Pharmaceuticals sector simultaneously. Practitioners should be prepared for varying levels of scrutiny as the distinct examiners may apply different interpretations of patentability criteria.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VYAS, KEYUR ANILKUMAR | 1 | 50.0% | +58.7% |
| BEANE, RANDALL L | 1 | 32.9% | +36.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18249058 | LIPOPEPTIDE FUSION INHIBITORS AS SARS-COV-2 ANTIVIRALS | BEANE, RANDALL L | 103d overdue |
| 18609709 | INHIBITOR OF SUV39H1 HISTONE METHYLTRANSFERASE FOR USE IN CANCER COMBINATION THERAPY | VYAS, KEYUR ANILKUMAR | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18609709 | INHIBITOR OF SUV39H1 HISTONE METHYLTRANSFERASE FOR USE IN CANCER COMBINATION THERAPY | VYAS, KEYUR ANILKUMAR | 1637 | §103DP | Non-Final OA | — | Pending | Mar 19, 2024 |
| 18249058 | LIPOPEPTIDE FUSION INHIBITORS AS SARS-COV-2 ANTIVIRALS | BEANE, RANDALL L | 1654 | §103 | Final Rejection | 103d overdue | Pending | Apr 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialINSERM has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Keyur Anilkumar Vyas has the most, with 1 of INSERM's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
